Literature DB >> 21372781

Passive administration of monoclonal antibodies against H. capsulatum and other fungal pathogens.

Allan J Guimarães1, Luis R Martinez, Joshua D Nosanchuk.   

Abstract

The purpose of the use of this methodology is 1) to advance our capacity to protect individuals with antibody or vaccine for preventing or treating histoplasmosis caused by the fungus Histoplasma capsulatum and 2) to examine the role of virulence factors as target for therapy. To generate mAbs, mice are immunized, the immune responses are assessed using a solid phase ELISA system developed in our laboratory, and the best responder mice are selected for isolation of splenocytes for fusion with hybridoma cells. C57BL/6 mice have been extensively used to study H. capsulatum pathogenesis and provide the best model for obtaining the data required. In order to assess the role of the mAbs in infection, mice are intraperitoneally administered with either mAb to H. capsulatum or isotype matched control mAb and then infected by either intravenous (i.v.), intraperitoneal (i.p.), or intranasal (i.n.) routes. In the scientific literature, efficacy of mAbs for fungal infections in mice relies on mortality as an end point, in conjunction with colony forming units (CFU) assessments at earlier time points. Survival (time to death) studies are necessary as they best represent human disease. Thus, efficacy of our intervention would not adequately be established without survival curves. This is also true for establishing efficacy of vaccine or testing of mutants for virulence. With histoplasmosis, the mice often go from being energetic to dead over several hours. The capacity of an intervention such as the administration of a mAb may initially protect an animal from disease, but the disease can relapse which would not be realized in short CFU experiments. In addition to survival and fungal burden assays, we examine the inflammatory responses to infection (histology, cellular recruitment, cytokine responses). For survival/time to death experiments, the mice are infected and monitored at least twice daily for signs of morbidity. To assess fungal burden, histopathology, and cytokine responses, the mice are euthanized at various times after infection. Animal experiments are performed according to the guidelines of the Institute for Animal Studies of the Albert Einstein College of Medicine.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21372781      PMCID: PMC3197409          DOI: 10.3791/2532

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  6 in total

Review 1.  Protective antibodies and endemic dimorphic fungi.

Authors:  J D Nosanchuk
Journal:  Curr Mol Med       Date:  2005-06       Impact factor: 2.222

2.  Responses of laboratory animals to some injectable anaesthetics.

Authors:  W Smith
Journal:  Lab Anim       Date:  1993-01       Impact factor: 2.471

3.  Monoclonal antibodies to heat shock protein 60 alter the pathogenesis of Histoplasma capsulatum.

Authors:  Allan J Guimarães; Susana Frases; Francisco J Gomez; Rosely M Zancopé-Oliveira; Joshua D Nosanchuk
Journal:  Infect Immun       Date:  2009-01-29       Impact factor: 3.441

4.  Antibodies to a cell surface histone-like protein protect against Histoplasma capsulatum.

Authors:  Joshua D Nosanchuk; Judith N Steenbergen; Li Shi; George S Deepe; Arturo Casadevall
Journal:  J Clin Invest       Date:  2003-10       Impact factor: 14.808

5.  Monoclonal antibody based ELISAs for cryptococcal polysaccharide.

Authors:  A Casadevall; J Mukherjee; M D Scharff
Journal:  J Immunol Methods       Date:  1992-09-18       Impact factor: 2.303

6.  Biological function and molecular mapping of M antigen in yeast phase of Histoplasma capsulatum.

Authors:  Allan Jefferson Guimarães; Andrew John Hamilton; Herbert Leonel de M Guedes; Joshua Daniel Nosanchuk; Rosely Maria Zancopé-Oliveira
Journal:  PLoS One       Date:  2008-10-17       Impact factor: 3.240

  6 in total
  4 in total

1.  Antibody therapy for histoplasmosis.

Authors:  Joshua D Nosanchuk; Rosely M Zancopé-Oliveira; Andrew J Hamilton; Allan J Guimarães
Journal:  Front Microbiol       Date:  2012-02-02       Impact factor: 5.640

2.  Surface architecture of histoplasma capsulatum.

Authors:  Allan J Guimarães; Mariana D de Cerqueira; Joshua D Nosanchuk
Journal:  Front Microbiol       Date:  2011-11-18       Impact factor: 5.640

Review 3.  The Einstein-Brazil Fogarty: A decade of synergy.

Authors:  Joshua D Nosanchuk; Murphy D Nosanchuk; Marcio L Rodrigues; Leonardo Nimrichter; Antonio C Campos de Carvalho; Louis M Weiss; David C Spray; Herbert B Tanowitz
Journal:  Braz J Microbiol       Date:  2015 Oct-Dec       Impact factor: 2.476

4.  Characterization of the antifungal functions of a WGA-Fc (IgG2a) fusion protein binding to cell wall chitin oligomers.

Authors:  Susie Coutinho Liedke; Daniel Zamith Miranda; Kamilla Xavier Gomes; Jorge Luis S Gonçalves; Susana Frases; Joshua D Nosanchuk; Marcio L Rodrigues; Leonardo Nimrichter; José Mauro Peralta; Allan J Guimarães
Journal:  Sci Rep       Date:  2017-09-22       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.